FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a compound which promotes production in a target cell of a mutant activin receptor type 2B (ACVR2B), or a pharmaceutically acceptable salt or hydrate thereof (embodiments), a pharmaceutical composition for use in the prevention or treatment of amyotrophic disease, muscular dystrophy or sarcopenia, method of treating amyotrophic disease, muscular dystrophy or sarcopenia and use of a compound or a pharmaceutically acceptable salt thereof or a hydrate for the purpose of preparing a drug for preventing or treating amyotrophic disease, muscular dystrophy or sarcopenia.
EFFECT: invention extends the range of agents promoting production of mutant activin receptor type 2B (ACVR2B) in the target cell.
29 cl, 3 dwg, 8 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2825834C2 |
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 |
|
RU2820247C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2777570C2 |
| COMPOSITIONS AND METHODS FOR REDUCING TAU EXPRESSION | 2016 |
|
RU2747734C2 |
| HSD17B13 OPTIONS AND THEIR APPLICATIONS | 2018 |
|
RU2760851C2 |
| THERAPY METHODS BASED ON CAR T-CELLS WITH INCREASED EFFICIENCY | 2016 |
|
RU2788131C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF HOMING-ENDONUCLEASE PD-1 | 2017 |
|
RU2781083C2 |
| COMPOSITIONS BASED ON STABILIZED FIBRONECTIN DOMAINS, METHODS AND APPLICATIONS THEREOF | 2011 |
|
RU2767543C2 |
